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Introduction: Chemsex	 in	 a	 European	 context	 is	 the	 use	 of	 any	 of	 the	 fol-
lowing	 drugs	 to	 facilitate	 sex:	 crystal	 methamphetamine,	 mephedrone	 and	
gamma-	hydroxybutyrate	(GHB)/gamma-	butyrolactone	(GBL)	and,	to	a	lesser	
extent,	 cocaine	 and	 ketamine.	 This	 study	 describes	 the	 prevalence	 of	 self-	










382	 (24.0%)	 reported	 chemsex	 and	 104	 (6.5%)	 reported	 injection	 of	 chemsex-	




seven	 (14.9%)	 accessed	 chemsex-	related	 services	 in	 the	 past	 year,	 38	 of	 whom	
(67%)	felt	the	service	met	their	needs.
Discussion: A	 quarter	 of	 participants	 self-	reported	 chemsex	 in	 the	 past	
12 months.	There	were	high	rates	of	harms	from	chemsex	across	all	countries,	
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INTRODUCTION
In	 2017,	 over	 25  000	 people	 were	 newly	 diagnosed	 with	
HIV	 in	 the	 European	 Union	 (EU)	 [1].	 Although	 the	 an-




A	 higher	 proportion	 of	 MSM	 use	 recreational	 drugs	
than	 the	 general	 population,	 a	 trend	 reported	 interna-
















of	 condomless	 anal	 intercourse,	 including	 with	 an	 HIV-	




Besides	 the	 transmission	 of	 infection,	 chemsex	 may	 be	
associated	with	other	harms	including	mental,	physical	and	
psychosocial	 as	 well	 as	 potential	 drug–	drug	 interactions	
with	 those	 taking	 antiretroviral	 therapy	 (ART)	 [9,10].	 For	
instance,	 there	has	been	a	reported	increase	in	deaths	due	
to	 GHB/GBL	 overdose	 in	 London,	 UK	 [11].	 The	 adverse	
impacts	of	drugs	associated	with	chemsex	on	mental	health,	
relationships	 and	 employment	 have	 also	 been	 described	
[7,12].
Across	 the	EU,	 there	 is	variability	 in	 the	provision	of	
dedicated	substance	use	services	for	MSM.	Although	some	
services,	 notably	 56	 Dean	 Street	 in	 London,	 do	 provide	






Europe	 [14,15]	and	 the	prevalence	 in	HIV-	positive	MSM	
has	been	reported	in	the	UK	and	Spain	[4,6];	however,	this	
is	 lacking	 in	other	European	countries	 such	as	 Italy	and	
Greece.
Despite	 knowing	 that	 rates	 of	 chemsex	 are	 higher	
among	 MSM	 with	 diagnosed	 HIV	 [16],	 little	 is	 known	
about	 how	 such	 use	 impacts	 their	 broader	 well-	being	
and	the	extent	of	unmet	healthcare	needs,	which	we	now	
seek	to	address	in	this	study	in	HIV-	positive	MSM	access-
ing	HIV	services	 in	 four	countries:	UK,	Spain,	 Italy	and	
Greece	[17,18].
METHODS
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The	 HIV	 services	 that	 participated	 were	 as	 follows:	 UK	
(four	 services):	 56	 Dean	 Street,	 Chelsea	 &	 Westminster	
NHS	Foundation	Trust,	London;	Kent	Community	NHS	
Foundation	 Trust;	 Northamptonshire	 Healthcare	 NHS	
Foundation	Trust;	Stevenage	&	Watford	clinics,	Chelsea	










The	 questionnaire	 was	 first	 designed	 in	 English.	 Once	
reviewed	 and	 approved	 by	 test	 patients	 and	 community	











All	 participants	 were	 asked	 to	 self-	report	 the	 following:	
age,	gender	and	if	they	were	born	in	the	country	in	which	















All	 participants	 were	 asked	 to	 self-	report	 whether	 they	
had	 used	 any	 recreational	 drugs	 in	 the	 last	 12  months	
and,	if	so,	to	select	which	ones	from	the	following	list:	am-
phetamine,	cannabis,	cocaine,	crystal	methamphetamine,	





Participants	 who	 self-	reported	 any	 recreational	 drug	
use	were	 further	asked	about	 the	use	of	any	of	 the	 fol-
lowing	 drugs	 to	 facilitate	 sex	 (‘chemsex’)	 –	 GHB/GBL,	
ketamine,	 crystal	 methamphetamine,	 mephedrone	 and	
cocaine	 –	 and	 the	 frequency	 of	 use	 (never,	 sometimes,	
often,	always,	don't	know)	for	each	drug.
Personal	harms	during,	or	as	a	result	of,	chemsex	were	
explored  with	 a	 series	 of	 questions	 relating	 to	 the	 last	
12 months:	(a)	experienced	unwanted	side-	effects,	(b)	any	




to	 self-	report	 if	 their	 chemsex	 use	 had	 a	 negative	 impact	
on	the	following	–	(a)	work,	(b)	family	and/or	friends,	(c)	
intimate	relationships	–	and	whether	they	had	accessed	any	





























nine	 centres,	 anonymized	 and	 transferred	 electronically	
to	 Chelsea	 &	 Westminster	 Foundation	 Trust	 for	 data-	
cleaning	and	analysis.
Statistical analyses









data).	 To	 see	 the	 effect	 of	 injecting	 drug	 use,	 we	 further	
stratified	 those	 engaging	 in	 chemsex	 by	 whether	 an	 indi-
vidual	 had	 self-	reported	 injecting	 chems	 in	 the	 previous	
12 months	or	not	and	tested	for	differences	between	both	
groups	using	the	same	tests	as	for	chemsex	use	(see	earlier).
We	 used	 logistic	 regression	 to	 explore	 factors	 associ-









Chems4EU	 was	 funded	 by	 a	 grant	 from	 Gilead's	 Voice	
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T A B L E  1 	 Demographic,	clinical	and	lifestyle	factors	of	1589	HIV-	positive	men	who	have	sex	with	men	who	completed	the	
questionnaire,	stratified	by	the	country	where	they	completed	the	questionnaire
All UK Spain Greece Italy
Total 1589 512 491 427 159
Age	[median	(IQR)] 38	(32–	46) 40	(32–	48) 40	(33–	47) 36	(32–	42) 39	(32–	45)
Gender	[n	(%)]
Male 1571	(98.9) 512	(100) 480	(97.8) 425	(99.5) 154	(96.9)
Trans 15	(0.9) 0	(0) 10	(2.0) 0	(0) 5	(3.1)
Blank 3	(0.2) 0	(0) 1	(0.2) 2	(0.5) 0	(0)
On	ART?	[n	(%)]
Yes 1525	(96.0) 477	(93.2) 476	(96.9) 419	(98.1) 153	(96.2)
No 41	(2.6) 16	(3.1) 13	(2.6) 7	(1.6) 5	(3.1)
Blank 23	(1.4) 19	(3.7) 2	(0.4) 1	(0.2) 1	(0.6)
If	on	ART,	last	HIV	viral	loadb	[n	(%)]
Detectable 94	(6.1) 31	(6.5) 25	(5.3) 23	(5.5) 15	(9.8)
Undetectable 1283	(84.1) 436	(91.4) 444	(93.3) 277	(66.1) 126	(82.4)
Don't	know 118	(7.7) 7	(1.5) 5	(1.1) 100	(23.9) 6	(3.9)
Blank 30	(2.0) 3	(0.6) 2	(0.4) 19	(4.5) 6	(3.9)
If	on	ARTb	,	number	of	missed	doses	in	past	2 weeks	[n	(%)]
0 1165	(76.4) 360	(75.5) 375	(78.8) 323	(77.1) 107	(70.0)
1–	2 251	(16.5) 76	(15.9) 77	(16.2) 64	(15.3) 34	(22.2)
3–	4 20	(1.3) 8	(1.7) 5	(1.1) 7	(1.7) 0	(0)
5–	6 6	(0.4) 3	(0.6) 2	(0.4) 1	(0.2) 0	(0)
7+ 21	(1.4) 5	(1.0) 8	(1.7) 6	(1.4) 2	(1.3)
Don't	know 1	(0.1) 0	(0) 0	(0) 1	(0.2) 0	(0)
Blank 61	(4.0) 25	(5.2) 9	(1.9) 17	(4.1) 10	(6.5)
Bacterial	STI	in	past	12 monthsa	[n	(%)]
No 1075	(67.7) 319	(62.3) 331	(67.4) 318	(74.5) 107	(67.3)
Yes 464	(29.2) 174	(34.0) 153	(31.2) 93	(21.8) 44	(27.7)
Don't	know 31	(2.0) 7	(1.4) 5	(1.0) 15	(3.5) 4	(2.5)
Blank 19	(1.2) 12	(2.3) 2	(0.4) 1	(0.2) 4	(2.5)
Ever	had	hepatitis	C?	[n	(%)]
No 1396	(87.9) 446	(87.1) 412	(83.9) 398	(93.2) 140	(88.1)
Yes 153	(9.6) 49	(9.6) 73	(14.9) 20	(4.7) 11	(6.9)
Don't	know 20	(1.3) 4	(0.8) 3	(0.6) 6	(1.4) 7	(4.4)
Blank 20	(1.3) 13	(2.5) 3	(0.6) 3	(0.7) 1	(0.6)
Number	sexual	partners	in	past	12 months	[n	(%)]
0 31	(2.0) 9	(1.8) 9	(1.8) 10	(2.3) 3	(1.9)
1 407	(25.6) 109	(21.3) 144	(29.3) 114	(26.7) 40	(25.2)
2–	3 265	(16.7) 78	(15.2) 93	(18.9) 67	(15.7) 27	(17.0)
4–	5 211	(13.3) 87	(17.0) 44	(9.0) 60	(14.1) 20	(12.6)
6–	10 186	(11.7) 72	(14.1) 49	(10.0) 51	(11.9) 14	(8.8)
11–	15 118	(7.4) 40	(7.8) 36	(7.3) 25	(5.9) 17	(10.7)
16–	20 99	(6.2) 25	(4.9) 41	(8.4) 23	(5.4) 10	(6.3)
> 21 223	(14.0) 73	(14.3) 63	(12.8) 60	(14.1) 27	(17.0)
Blank 49	(3.1) 19	(3.7) 12	(2.4) 17	(4.0) 1	(0.6)
(Continues)
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frequently	used	drug	overall	(399,	56.3%)	followed	by	co-
caine	(301,	42.5%)	and	GHB/GBL	(247,	34.8%)	(Table 2a).	
Recreational	 drug	 use	 was	 more	 common	 in	 the	 UK	
(271/512,	 52.9%),	 followed	 by	 Spain	 (223/491,	 45.4%),	
Greece	(160/427,	37.4%)	and	Italy	(55/159,	34.6%).
Chemsex
Almost	 a	 quarter	 (24.0%,	 382)	 of	 individuals	 reported	
chemsex	 in	 the	 previous	 12  months.	 Following	 a	 simi-
lar	 pattern	 to	 recreational	 drug	 use,	 the	 highest	 propor-
tion	 was	 in	 the	 UK	 (168/512,	 32.8%),	 followed	 by	 Spain	
(113/491,	 23.0%),	 Greece	 (82/427,	 19.2%)	 and	 the	 least	
reports	 in	 Italy	 (19/159,	 11.9%)	 (Table  2b).	 Among	 men	
engaging	in	chemsex,	the	most	commonly	used	drug	was	
GHB/GBL	 (268,	 70.2%),	 followed	 by	 crystal	 metham-
phetamine	 (256,	 67.0%),	 cocaine	 (227,	 59.4%),	 mephed-
rone	 (185,	 48.4%)	 and	 ketamine	 (122,	 31.9%).	 The	 most	
common	chemsex	drug	used	by	country	was:	UK	(crystal	
methamphetamine:	 125,	 74.4%),	 Spain	 (GHB/GBL:	 84,	








was	 crystal	 methamphetamine	 (87,	 83.7%)	 followed	 by	
mephedrone	 (46,	44.2%),	 cocaine	 (30,	28.8%),	GHB/GBL	
(27,	26.0%)	and	ketamine	(25;	24.0%).
Reported impact of chemsex
Of	382	participants	who	had	engaged	in	chemsex	within	
the	past	12 months,	155	(40.6%)	reported	unwanted	side-	
effects	 as	 a	 result	 of	 this	 drug	 use,	 81	 (21.2%)	 reported	
unwanted	 side-	effects	 as	 a	 result	 of	 withdrawal	 from	





chemsex	 session	 (Table  3).	 In	 the	 previous	 12  months,	
those	 engaging	 in	 chemsex	 reported	 a	 negative	 impact	
from	 their	 chemsex	 on	 work	 (96,	 25.1%),	 friends	 and/or	
family	(93,	24.3%)	and	intimate	relationships	(108,	28.3%).
In	 relation	 to	 chemsex,	 57	 (14.9%)	 accessed	 profes-
sional	services	in	the	past	year,	ranging	from	19%	(32/168)	
in	the	UK	to	5%	(1/19)	in	Italy.	Of	these,	38	(67%)	felt	the	





5).	 In	 multivariate	 analysis,	 individuals	 who	 reported	
having	 a	 bacterial	 STI	 in	 the	 previous	 year	 [50.0%	 vs.	
22.6%,	respectively;	adjusted	odds	ratio	(aOR)	=	2.35;	95%	
All UK Spain Greece Italy
Fisted	or	been	fisted	in	past	12 months	[n	(%)]
No 1317	(82.9) 405	(79.1) 437	(89.0) 332	(77.8) 143	(89.9)
Yes 205	(12.9) 81	(15.8) 40	(8.1) 69	(16.2) 15	(9.4)
Don't	know 10	(0.6) 2	(0.4) 5	(1.0) 3	(0.7) 0	(0)
Blank 57	(3.6) 24	(4.7) 9	(1.8) 23	(5.4) 1	(0.6)
Are	you	happy	with	your	sex	life?	[n	(%)]
Very	happy 381	(24.0) 107	(20.9) 153	(31.2) 86	(20.1) 35	(22.0)
Quite	happy 629	(39.6) 189	(36.9) 185	(37.7) 175	(41.0) 80	(50.3)
Unsure/neutral 398	(25.0) 134	(26.2) 109	(22.2) 124	(29.0) 31	(19.5)
Quite	unhappy 96	(6.0) 47	(9.2) 23	(4.7) 17	(4.0) 9	(5.7)
Very	unhappy 39	(2.5) 16	(3.1) 12	(2.4) 8	(1.9) 3	(1.9)




T A B L E  1 	 (Continued)
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T A B L E  2 	 (a)	Drugs	taken	by	individuals	who	self-	reported	recreational	drug	use	in	the	previous	12 months,	stratified	by	country	of	
completion	of	questionnaire;	(b)	drugs	taken	by	individuals	who	self-	reported	chemsex	use	in	the	previous	12 months,	stratified	by	country	
of	completion	of	questionnaire.	Data	are	presented	as	n	(%)
All UK Spain Greece Italy
(a)	Self-	reported	recreational	drug	use	(N	=	709)
Total 709 271 223 160 55
Cannabis 399	(56.3) 126	(46.5) 116	(52.0) 119	(74.4) 38	(69.1)
Cocaine 301	(42.5) 134	(49.4) 92	(41.3) 105	(65.6) 20	(36.4)
GHB/GBL 247	(34.8) 116	(42.8) 71	(31.8) 48	(30.0) 12	(21.8)
Crystal	
methamphetamine
238	(33.6) 134	(49.4) 48	(21.5) 53	(33.1) 3	(5.5)
Ecstasy 198	(27.9) 91	(33.6) 71	(31.8) 35	(21.9) 1	(1.8)
Mephedrone 136	(19.2) 70	(25.8) 30	(13.5) 33	(20.6) 3	(5.5)
Ketamine 123	(17.3) 63	(23.2) 37	(16.6) 20	(12.5) 3	(5.5)
Amphetamine 80	(11.3) 36	(13.3) 26	(11.7) 15	(9.4) 3	(5.5)
LSD 20	(2.8) 4	(1.5) 8	(3.6) 8	(5.0) 0	(0)
Heroin 5	(0.7) 1	(0.4) 3	(1.3) 1	(0.6) 0	(0)
Other 36	(5.1) 1	(0.4) 30	(13.5) 5	(3.1) 0	(0)
(b)	Self-	reported	chemsex	use	(N	=	382)
382 168 113 82 19
GHB/GBL
Yes 268	(70.2) 117	(69.6) 84	(74.3) 55	(67.1) 12	(63.2)
No 50	(13.1) 23	(13.7) 8	(7.1) 19	(23.2) 0	(0)
Don't	know 7	(1.8) 0	(0) 6	(5.3) 1	(1.2) 0	(0)
Blank 57	(14.9) 28	(16.7) 15	(13.3) 7	(8.5) 7	(36.8)
Crystal	methamphetamine
Yes 256	(67.0) 125	(74.4) 80	(70.8) 47	(57.3) 4	(21.1)
No 56	(14.7) 23	(13.7) 8	(7.1) 24	(29.3) 1	(5.3)
Don't	know 3	(0.8) 0	(0) 3	(2.7) 0	(0) 0	(0)
Blank 67	(17.5) 20	(11.9) 22	(19.5) 11	(13.4) 14	(73.7)
Cocaine
Yes 227	(59.4) 89	(53.0) 78	(69.0) 45	(54.9) 15	(78.9)
No 84	(22.0) 45	(26.8) 12	(10.6) 27	(32.9) 0	(0)
Don't	know 7	(1.8) 0	(0) 7	(6.2) 0	(0) 0	(0)
Blank 64	(16.8) 34	(20.2) 16	(14.2) 10	(12.2) 4	(21.1)
Mephedrone
Yes 185	(48.4) 78	(46.4) 64	(56.6) 39	(47.6) 4	(21.1)
No 99	(25.9) 50	(29.8) 18	(15.9) 31	(37.8) 0	(0)
Don't	know 4	(1.0) 0	(0) 4	(3.5) 0	(0) 0	(0)
Blank 94	(24.6) 40	(23.8) 27	(23.9) 12	(14.6) 15	(78.9)
Ketamine
Yes 122	(31.9) 40	(23.8) 69	(61.1) 11	(13.4) 2	(10.5)
No 134	(35.1) 69	(41.1) 15	(13.3) 50	(61.0) 0	(0)
Don't	know 3	(0.8) 0	(0) 2	(1.8) 1	(1.2) 0	(0)
Blank 123	(32.2) 59	(35.1) 27	(23.9) 20	(24.4) 17	(89.5)
Abbreviations:	GHB,	gamma-	hydroxybutyrate;	GBL,	gamma-	butyrolactone.
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T A B L E  3 	 Self-	reported	impact	of	chemsex	on	lifestyle	for	382	chemsex	users,	stratified	by	country	of	completion	of	questionnaire.	Data	
are	presented	as	n	(%)
All UK Spain Greece Italy
Total 1589 512 491 427 159
Chemsexb	 382	(24.0) 168	(32.8) 113	(23.0) 82	(19.2) 19	(11.9)
Slamsexb	 104	(6.5) 68	(13.3) 14	(2.9) 20	(4.7) 2	(1.3)
Unwanted	side-	effectsa	
Yes 155	(40.6) 67	(39.9) 47	(41.6) 34	(41.5) 7	(36.8)
No 194	(50.8) 88	(52.4) 53	(46.9) 41	(50.0) 12	(63.2)
Don't	know 29	(7.6) 10	(6.0) 12	(10.6) 7	(8.5) 0	(0)
Blank 4	(1.0) 3	(1.8) 1	(0.9) 0	(0) 0	(0)
Unwanted	side-	effects	from	drug	withdrawala	
Yes 81	(21.2) 47	(28.0) 29	(25.7) 5	(6.1) 0	(0)
No 259	(67.8) 103	(61.3) 69	(61.1) 68	(82.9) 19	(100)
Don't	know 37	(9.7) 14	(8.3) 14	(12.4) 9	(11.0) 0	(0)
Blank 5	(1.3) 4	(2.4) 1	(0.9) 0	(0) 0	(0)
Sought	emergency	medical	carea	
Yes 27	(7.1) 11	(6.5) 12	(10.6) 1	(1.2) 3	(15.8)
No 347	(90.8) 153	(91.1) 98	(86.7) 80	(97.6) 16	(84.2)
Don't	know 3	(0.8) 0	(0) 2	(1.8) 1	(1.2) 0	(0)
Blank 5	(1.3) 4	(2.4) 1	(0.9) 0	(0) 0	(0)
Injury	related	to	injecting	drugsa	
Yes 23	(6.0) 12	(7.1) 8	(7.1) 2	(2.4) 1	(5.3)
No 351	(91.9) 152	(90.5) 103	(91.2) 78	(95.1) 18	(94.7)
Don't	know 2	(0.5) 0	(0) 1	(0.9) 1	(1.2) 0	(0)
Blank 6	(1.6) 4	(2.4) 1	(0.9) 1	(1.2) 0	(0)
Drug	overdosea	
Yes 28	(7.3) 11	(6.5) 8	(7.1) 8	(9.8) 1	(5.3)
No 340	(89.0) 151	(89.9) 102	(90.3) 71	(86.6) 16	(84.2)
Don't	know 10	(2.6) 3	(1.8) 2	(1.8) 3	(3.7) 2	(10.5)
Blank 4	(1.0) 3	(1.8) 1	(0.9) 0	(0) 0	(0)
Sex	without	full	consenta	
Yes 23	(6.0) 13	(7.7) 5	(4.4) 4	(4.9) 1	(5.3)
No 337	(88.2) 146	(86.9) 103	(91.2) 77	(93.9) 11	(57.9)
Don't	know 18	(4.7) 6	(3.6) 4	(3.5) 1	(1.2) 7	(36.8)
Blank 4	(1.0) 3	(1.8) 1	(0.9) 0	(0) 0	(0)
Chemsex	has	negatively	impacted	on	your:b	
Work
Yes 96	(25.1) 53	(31.5) 29	(25.7) 10	(12.2) 4	(21.1)
No 267	(69.9) 104	(61.9) 82	(72.6) 68	(82.9) 13	(68.4)
Don't	know 14	(3.7) 7	(4.2) 1	(0.9) 4	(4.9) 2	(10.5)
Blank 5	(1.3) 4	(2.4) 1	(0.9) 0	(0) 0	(0)
Friends/family
Yes 93	(24.3) 44	(26.2) 33	(29.2) 12	(14.6) 4	(21.1)
No 265	(69.4) 111	(66.1) 74	(65.5) 66	(80.5) 14	(73.7)
Don't	know 20	(5.2) 10	(6.0) 5	(4.4) 4	(4.9) 1	(5.3)
(Continues)





having	 engaged	 in	 fisting	 in	 the	 past	 12  months	 [31.9%	
vs.	6.9%;	aOR	=	4.87;	95%	CI:	3.42–	6.93]	were	more	likely	
to	report	chemsex	use.	In	addition,	those	reporting	to	be	




engaging	 in	chemsex	were	more	 likely	 to	report	missed	





Participants	 who	 reported	 engaging	 in	 chemsex	 and	
who	also	reported	slamsex	(n = 104),	as	compared	with	










Reported impact of slamsex
Of	 104	 participants	 engaging	 in	 chemsex	 who	 reported	
slamsex	 within	 the	 previous	 12  months,	 57	 (54.8%)	 re-
ported	 unwanted	 side-	effects	 as	 a	 result	 of	 chemsex,	 39	
(37.5%)	reported	unwanted	side-	effects	as	a	result	of	with-
drawal	from	chemsex	drugs	and	19	(18.3%)	reported	that	










of	 HIV-	positive	 MSM	 attending	 HIV	 services	 in	 the	 nine	
clinics	in	four	countries	surveyed,	with	the	most	commonly	
used	 chemsex	 drug	 being	 GHB/GBL,	 closely	 followed	 by	
crystal	methamphetamine.	There	was	wide	variation	in	the	
All UK Spain Greece Italy
Blank 4	(1.0) 3	(1.8) 1	(0.9) 0	(0) 0	(0)
Intimate	relationships
Yes 108	(28.3) 48	(28.6) 38	(33.6) 15	(18.3) 7	(36.8)
No 252	(66.0) 109	(64.9) 70	(61.9) 63	(76.8) 10	(52.6)
Don't	know 17	(4.5) 8	(4.8) 4	(3.5) 4	(4.9) 1	(5.3)
Blank 5	(1.3) 3	(1.8) 1	(0.9) 0	(0) 1	(5.3)
Access	professional	services	in	relation	to	your	chemsexb	
Yes 57	(14.9) 32	(19.0) 18	(15.9) 6	(7.3) 1	(5.3)
No 310	(81.2) 131	(78.0) 89	(78.8) 74	(90.2) 16	(84.2)
Don't	know 8	(2.1) 1	(0.6) 3	(2.7) 2	(2.4) 2	(10.5)
Blank 7	(1.8) 4	(2.4) 3	(2.7) 0	(0) 0	(0)
If	yes,	did	the	service	meet	your	needs?
Yes 38	(66.7) 20	(62.5) 13	(72.2) 4	(66.7) 1	(100)
No 9	(15.8) 5	(15.6) 2	(11.1) 2	(33.3) 0	(0)
Don't	know 6	(10.5) 3	(9.4) 3	(16.7) 0	(0) 0	(0)
Blank 4	(7.0) 4	(12.5) 0	(0) 0	(0) 0	(0)
aDuring,	or	as	a	result	of,	chemsex	within	the	last	12 months
bWithin	the	last	12 months
T A B L E  3 	 (Continued)
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T A B L E  4 	 Demographic,	clinical	and	lifestyle	factors	of	1589	participants	stratified	by	whether	or	not	they	engaged	in	chemsex
Non- chems user Chems user p
Total 1207 382
Age	(years)	[median	(IQR)] 38	(32–	46) 39	(32–	45) 0.85
Country














































similar	 chemsex	 prevalence	 in	 the	 UK	 [6]	 and	 Spain	 [4].	
In	Italy,	despite	 the	smaller	sample	 than	in	other	centres	





A	 major,	 novel	 finding	 of	 this	 study	 consists	 of	 self-	
reported	 impacts	 and	 harms	 of	 chemsex	 among	 HIV-	
positive	MSM.	The	most	commonly	reported	impacts	were	
unwanted	 side-	effects	 in	 40.6%	 of	 participants.	 Of	 those	
engaging	 in	 chemsex,	 21.2%	 reported	 symptoms	 of	 drug	










bacterial	 and	 viral,	 including	 hepatitis	 C,	 and	 associated	
with	being	more	unhappy	with	one’s	sex	life)	and	poten-
tially	 HIV	 management	 through	 missed	 ART	 doses.	 In	
addition,	 those	engaging	in	chemsex	were	more	likely	to	






















It	 is	 notable	 that	 all	 rates	 of	 harms	 were	 more	 likely	
to	be	self-	reported	in	slamsex	users	than	in	those	engag-
ing	in	chemsex	who	did	not	inject	(Tables	S3	and	S4).	In	
particular,	 18%	 of	 those	 reporting	 slamsex	 had	 accessed	
emergency	 medical	 care	 in	 relation	 to	 their	 drug	 use	 in	
the	previous	12 months	compared	with	3%	of	participants	
who	reported	chemsex	but	who	did	not	inject	drugs.











Non- chems user Chems user p
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slower	 than	 anticipated	 during	 the	 study	 period	 and	 so	
the	Italian	sample	size	was	less	than	half	that	of	the	other	
countries	 surveyed.	 As	 the	 survey	 was	 a	 self-	reported	
questionnaire,	 some	 of	 the	 information,	 such	 as	 that	
around	sexually	transmitted	infections,	is	likely	to	be	less	
accurate	 than	 that	 from	 medical	 record	 review.	We	 lack	
data	on	the	numbers	of	individuals	approached	who	de-
clined	to	participate	and	although	we	attempted	to	offer	







aOR (95% CI) p
Country
UK <0.0001 <0.0001 <0.0001
Italy 0.28	(0.17–	0.46) 0.28	(0.16–	0.49) 0.24	(0.13–	0.45)
Greece 0.49	(0.36–	0.66) 0.47	(0.33–	0.66) 0.49	(0.34–	0.70)







No < 0.0001 < 0.0001 < 0.0001
Yes 3.55	(2.78–	4.54) 2.35	(1.77–	3.12) 2.26	(1.69–	3.03)
Unknown 1.97	(1.04–	3.73) 2.77	(1.24–	6.20) 2.50	(1.05–	5.91)
Ever	had	hepatitis	C?
Yes < 0.0001 0.002 0.007
No 1.93	(1.35–	2.74) 1.70	(1.12–	2.57) 1.67	(1.09–	2.56)
Unknown 0.37	(0.13–	1.05) 0.20	(0.06–	0.71) 0.20	(0.04–	0.97)
Number	of	sexual	partners	in	the	previous	12 months
0 < 0.0001 < 0.0001 < 0.0001
1 2.82	(0.37–	21.33) 2.89	(0.38–	22.12) 2.77	(0.36–	21.27)
2–	3 6.14	(0.82–	46.17) 4.70	(0.62–	35.85) 4.69	(0.61–	35.92)
4–	5 10.32	(1.37–	77.49) 6.97	(0.91–	53.16) 6.29	(0.82–	48.14)
6–	10 11.64	(1.55–	87.58) 7.34	(0.96–	56.09) 7.23	(0.94–	55.44)
>10 21.97	(2.97–	162.54) 11.61	(1.54–	87.37) 10.62	(1.41–	80.18)
Blank 6.75	(0.81–	56.21) 4.15	(0.30–	57.17) 3.93	(0.23–	68.09)
Fisted	or	been	fisted	in	past	12 months
No < 0.0001 < 0.0001 < 0.0001
Yes 6.43	(4.71–	8.78) 4.87	(3.42–	6.93) 4.74	(3.30–	6.81)
Unknown 1.26	(0.70–	2.28) 2.01	(0.82–	4.93) 1.71	(0.61–	4.75)
Are	you	happy	with	your	sex	life?
Very	happy < 0.0001 < 0.0001 0.001
Quite	happy 1.44	(1.04–	2.00) 1.35	(0.93–	1.96) 1.38	(0.94–	2.01)
Unsure/neutral 2.19	(1.55–	3.08) 2.14	(1.45–	3.17) 2.22	(1.48–	3.32)
Quite	unhappy 2.14	(1.29–	3.58) 1.60	(0.89–	2.90) 1.54	(0.83–	2.85)
Very	unhappy 3.83	(1.92–	7.61) 3.39	(1.47–	7.78) 3.37	(1.36–	8.32)
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the	 survey	 systemically	 as	 described	 we	 cannot	 rule	 out	
selection	bias.	In	all	four	countries,	the	sample	comprises	
HIV-	positive	MSM	in	predominantly	large	urban	centres	
with	 big	 gay	 communities	 (London,	 Madrid,	 Barcelona,	















In	 conclusion,	 this	 study	 indicates	 the	 particular	 im-
portance	of	sexual	health	and	psychological	needs	of	HIV-	
positive	 MSM	 engaging	 in	 chemsex,	 paying	 particular	
attention	to	those	engaging	in	injecting	drug	use	practices.
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